Mutations in Two Genes Encoding Different Subunits of a Receptor Signaling Complex Result in an Identical Disease Phenotype
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), also known as "Nasu-Hakola disease," is a globally distributed recessively inherited disease leading to death during the 5th decade of life and is characterized by early-onset progressive dementia and bone cysts. Elsewhere, we have identified PLOSL mutations in TYROBP (DAP12), which codes for a membrane receptor component in natural-killer and myeloid cells, and also have identified genetic heterogeneity in PLOSL, with some patients carrying no mutations in TYROBP. Here we complete the molecular pathology of PLOSL by identifying TREM2 as the second PLOSL gene. TREM2 forms a receptor signaling complex with TYROBP and triggers activation of the immune responses in macrophages and dendritic cells. Patients with PLOSL have no defects in cell-mediated immunity, suggesting a remarkable capacity of the human immune system to compensate for the inactive TYROBP-mediated activation pathway. Our data imply that the TYROBP-mediated signaling pathway plays a significant role in human brain and bone tissue and provide an interesting example of how mutations in two different subunits of a multisubunit receptor complex result in an identical human disease phenotype.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Homozygous loss-of-function mutations in TREM2 or DAP12 genes cause Nasu–Hakola disease (NHD), a rare genetic disorder characterized by fatal presenile dementia and bone cysts [38, 39].”
From TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) · cites this paper as [39]
In the citing paper
“TYROBP is a transmembrane adaptor protein for TREM2, SIRPβ1, and CR3 receptors, which are known to be involved in AD pathogenesis [90–92].”
From Sex-specific DNA methylation differences in Alzheimer’s disease pathology (2021) · cites this paper as [92]
In the citing paper
“Homozygous Q33X, Y38C and T66M variants have been identified in patients with Nasu-Hakola disease [44, 47, 95].”
From TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation (2021) · cites this paper as [95]
In the citing paper
“A number of mutations in PLCG2 (about 75%), that have been previously implicated in various inflammatory diseases [92–102], actually map to the autoinhibitory interface on the PLCγ2 model structure and can be considered as pathogenic (Fig. 2c)”
From TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation (2021) · cites this paper as [95]
In the citing paper
“Even more rare loss-of-function mutations of TREM2 or DAP12 cause a form of recessively inherited presenile dementia, called Nasu-Hakola disease (126, 127).”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [126]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Bouchon, A., Dietrich, J., & Colonna, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.4991 · Cited by 1,284 · cited 4×
“2001a), whereas TREM2 is expressed on macrophages and monocyte-derived dendritic cells, suggesting that TREM2 plays a role in chronic, rather than in acute, inflammation (Bouchon et al. 2000).”
BackgroundInfluentialTREM-1 amplifies inflammation and is a crucial mediator of septic shock
Bouchon, A., Facchetti, F., Weigand, M. A., & Colonna, M. (2001) · Nature · doi:10.1038/35074114 · Cited by 1,090 · cited 2×
“TREM1 is strongly up-regulated in cells that mediate acute inflammatory responses to bacterial infection (i.e., neutrophils and monocytes) (Bouchon et al. 2001a), whereas TREM2 is expressed on macrophages and monocyte-derived dendritic cells, suggesting that TREM2 plays a role in chronic, rather…”
BackgroundImmunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells
Lanier, L. L., Corliss, B. C., Wu, J., Leong, C., & Phillips, J. H. (1998) · Nature · doi:10.1038/35642 · Cited by 904 · cited 5×
“This has been shown to disrupt the association with (McVicar et al. 1998; Bakker et al. 1999), as well as the cell-surface expression of, TYROBP (Lanier et al. 1998b; Smith et al. 1998).”
BackgroundInfluentialVitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R., Moretta, L., & Moretta, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2065 · Cited by 748 · cited 1×
“1) (Vitale et al. 1998), MDL1 (chromosome 7q33) (Bakker et al. 1999), CD94 (chromosome 12p13.”
Association of DAP12 with Activating CD94/NKG2C NK Cell Receptors
Lanier, L. L., Corliss, B., Wu, J., & Phillips, J. H. (1998) · Immunity · doi:10.1016/s1074-7613(00)80574-9 · Cited by 559 · cited 5×
“This has been shown to disrupt the association with (McVicar et al. 1998; Bakker et al. 1999), as well as the cell-surface expression of, TYROBP (Lanier et al. 1998b; Smith et al. 1998).”
BackgroundInfluentialLoss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts
Paloneva, J., Kestilä, M., Wu, J., Salminen, A., Böhling, T., Ruotsalainen, V., Hakola, P., Bakker, A. B. H., Phillips, J. H., Pekkarinen, P., et al. (2000) · Nature Genetics · doi:10.1038/77153 · Cited by 460 · cited 6×
“Interestingly, patients with PLOSL who are homozygous for mutations in either TREM2 or TYROBP display identical CNS and bone manifestations (table 2)—and no immunological symptoms (Paloneva et al. 2000).”
BackgroundInfluentialSelf-citationBouchon, A., Hernández-Munain, C., Cella, M., & Colonna, M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.8.1111 · Cited by 460 · cited 2×
“TREM1 is strongly up-regulated in cells that mediate acute inflammatory responses to bacterial infection (i.e., neutrophils and monocytes) (Bouchon et al. 2001a), whereas TREM2 is expressed on macrophages and monocyte-derived dendritic cells, suggesting that TREM2 plays a role in chronic, rather…”
BackgroundLy-49D and Ly-49H associate with mouse DAP12 and form activating receptors.
Smith, K. M., Wu, J., Bakker, A. B. H., Phillips, J. H., & Lanier, L. L. (1998) · PubMed · Cited by 277
Cutting Edge: Ly-49D and Ly-49H Associate with Mouse DAP12 and Form Activating Receptors
Smith, K. M., Wu, J., Bakker, A. B. H., Phillips, J. H., & Lanier, L. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.1.7 · Cited by 249 · cited 1×
“This has been shown to disrupt the association with (McVicar et al. 1998; Bakker et al. 1999), as well as the cell-surface expression of, TYROBP (Lanier et al. 1998b; Smith et al. 1998).”
BackgroundMutations in PATCHED-1, the receptor for SONIC HEDGEHOG, are associated with holoprosencephaly
Ming, J. E., Kaupas, M. E., Roessler, E., Brunner, H. G., Golabi, M., Tekin, M., Stratton, R. F., Sujansky, E., Bale, S. J., & Muenke, M. (2002) · Human Genetics · doi:10.1007/s00439-002-0695-5 · Cited by 244
Research works printed but not linked: 1
- Tranebjærg, 2000, Polycystic lipomembranous osteodysplasia, Tidsskr Nor Laegeforen, 120, 3196
Cited by
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253
“[138] Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, et al.”
BackgroundMicroglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935
Microglial physiology: unique stimuli, specialized responses
Ransohoff, R. M., & Perry, V. H. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132528 · Cited by 1,858
“The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2.”
BackgroundInfluentialMicroglia emerge as central players in brain disease
Salter, M. W., & Stevens, B. (2017) · Nature Medicine · doi:10.1038/nm.4397 · Cited by 1,767
TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736
“…homozygous for rare mutations that impair expression of either TREM2 or DAP12, develop lethal forms of progressive, early-onset dementia such as Nasu-Hakola disease (NHD) and frontotemporal dementia (Guerreiro et al., 2013a; Guerreiro et al., 2013c; Kleinberger et al., 2014; Paloneva et al., 2002).”
InfluentialDefeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
Gong, T., Liu, L., Jiang, W., & Zhou, R. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0215-7 · Cited by 1,672
Microglia Biology: One Century of Evolving Concepts
Prinz, M., Jung, S., & Priller, J. (2019) · Cell · doi:10.1016/j.cell.2019.08.053 · Cited by 1,525
The molecular understanding of osteoclast differentiation
Asagiri, M., & Takayanagi, H. (2007) · Bone · doi:10.1016/j.bone.2006.09.023 · Cited by 1,363
Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357
“Homozygous mutations in TREM2 are associated with autosomal recessive forms of dementia with bone cysts and fractures (95).”
Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease
Prinz, M., & Priller, J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3722 · Cited by 1,329
Microglial priming in neurodegenerative disease
Perry, V. H., & Holmes, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.38 · Cited by 1,127
Takahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124
Microglial cell origin and phenotypes in health and disease
Saijo, K., & Glass, C. K. (2011) · Nature Reviews Immunology · doi:10.1038/nri3086 · Cited by 1,100
“In humans, homozygous loss-of-function mutations affecting either DAP12 or TREM2 result in Nasu–Hakola diseas”
BackgroundYeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C., & Sheng, M. (2016) · Neuron · doi:10.1016/j.neuron.2016.06.015 · Cited by 943
TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Wang, Y., Ulland, T. K., Ulrich, J. D., Song, W., Tzaferis, J. A., Hole, J. T., Yuan, P., Mahan, T. E., Shi, Y., Gilfillan, S., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151948 · Cited by 840
“TREM2 is a cell surface receptor of the Ig superfamily that is expressed in microglia of the central nervous system and in other tissue macrophages, and binds phospholipids and other polyanionic ligands (Paloneva et al., 2002; Daws et al., 2003; Cannon et al., 2012; Wang et al., 2015).”
BackgroundCostimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis
Koga, T., Inui, M., Inoue, K., Kim, S., Suematsu, A., Kobayashi, E., Iwata, T., Ohnishi, H., Matozaki, T., Kodama, T., et al. (2004) · Nature · doi:10.1038/nature02444 · Cited by 828
“The mutations of the ITAM-harbouring adaptors and their associating receptors are related to pathological conditions in the skeletal syste”
BackgroundTREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge
Nugent, A. A., Lin, K., van Lengerich, B., Lianoglou, S., Przybyla, L., Davis, S. S., Llapashtica, C., Wang, J., Kim, D. J., Xia, D., et al. (2020) · Neuron · doi:10.1016/j.neuron.2019.12.007 · Cited by 798
TREM2 — a key player in microglial biology and Alzheimer disease
Ulland, T. K., & Colonna, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0072-1 · Cited by 735
Myelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes-Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 728
“Surprisingly, mutations in primarily microglial genes such as the colony stimulating factor 1 receptor (CSF1R) in hereditary diffuse leukoencephalopathy with spheroids (HDLS), or the triggering receptor expressed on myeloid cells-2 (TREM2) and its adaptor protein TYROBP in Nasu Hakola disease lead to late-onset demyel…”
BackgroundTREMs in the immune system and beyond
Colonna, M. (2003) · Nature Reviews Immunology · doi:10.1038/nri1106 · Cited by 701
“Unexpectedly, recent analysis of patients with Nasu-Hakola disease, who have an intact gene encoding DAP12 and normal expression levels of DAP12, indicated loss-of-function mutations in TREM2 (Ref”
BackgroundFilipello, F., Morini, R., Corradini, I., Zerbi, V., Canzi, A., Michalski, B., Erreni, M., Markicevic, M., Starvaggi-Cucuzza, C., Otero, K., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.04.016 · Cited by 695
“Homozygous, loss-of-function mutations in Trem2 or its signaling adapter DAP12 cause the autosomal recessive disorder Nasu–Hakola disease (Paloneva et al., 2002), a rare pathology characterized by early-onset dementia, demyelination, and bone cyst-like lesions.”
BackgroundCutting Edge: TREM-2 Attenuates Macrophage Activation
Turnbull, I. R., Gilfillan, S., Cella, M., Aoshi, T., Miller, M., Piccio, L., Hernandez, M., & Colonna, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.3520 · Cited by 688
“These patients develop Nasu-Hakola disease, which is characterized by bone cysts and demyelinating lesions in the CNS that ultimately result in fatal presenile dementia (3).”
BackgroundFriedman, B. A., Srinivasan, K., Ayalon, G., Meilandt, W. J., Lin, H., Huntley, M. A., Cao, Y., Lee, S.-H., Haddick, P. C. G., Ngu, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.066 · Cited by 662
Bohlen, C. J., Bennett, F. C., Tucker, A. F., Collins, H. Y., Mulinyawe, S. B., & Barres, B. A. (2017) · Neuron · doi:10.1016/j.neuron.2017.04.043 · Cited by 658
The TREM receptor family and signal integration
Klesney-Tait, J., Turnbull, I. R., & Colonna, M. (2006) · Nature Immunology · doi:10.1038/ni1411 · Cited by 589
Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)
Atagi, Y., Liu, C.-C., Painter, M. M., Chen, X.-F., Verbeeck, C., Zheng, H., Li, X., Rademakers, R., Kang, S. S., Xu, H., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679043 · Cited by 587
Microglia and Central Nervous System–Associated Macrophages—From Origin to Disease Modulation
Prinz, M., Masuda, T., Wheeler, M. A., & Quintana, F. J. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-093019-110159 · Cited by 584
Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis
Sierra, A., Abiega, O., Shahraz, A., & Neumann, H. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00006 · Cited by 574
Rademakers, R., Baker, M., Nicholson, A. M., Rutherford, N. J., Finch, N., Soto-Ortolaza, A., Lash, J., Wider, C., Wojtas, A., DeJesus-Hernandez, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.1027 · Cited by 571
“NHD is caused by recessive loss-of-function mutations in the DAP12-TREM2 protein comple”
BackgroundLate onset Alzheimer’s disease genetics implicates microglial pathways in disease risk
Efthymiou, A. G., & Goate, A. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0184-x · Cited by 562
“This is driven by loss of function in macrophages in many tissues, including microglia [65].”
BackgroundHagemeyer, N., Hanft, K.-M., Akriditou, M.-A., Unger, N., Park, E. S., Stanley, E. R., Staszewski, O., Dimou, L., & Prinz, M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1747-1 · Cited by 558
“For example, mutations in the colony stimulating factor-1 receptor (CSF-1R) in patients with hereditary diffuse leukoencephalopathy with spheroids (HDLS, [55]), in the triggering receptor expressed on myeloid cell (TREM) 2 inducing Nasu–Hakola disease [44] or in the ubiquitin specific peptidase (USP) 18 causing a dest…”
BackgroundNew insights on the role of microglia in synaptic pruning in health and disease
Hong, S., Dissing-Olesen, L., & Stevens, B. (2016) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.12.004 · Cited by 557
TREM2 sustains microglial expansion during aging and response to demyelination
Poliani, P. L., Wang, Y., Fontana, E., Robinette, M. L., Yamanishi, Y., Gilfillan, S., & Colonna, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77983 · Cited by 525
“Alternatively, the development of NHD may require not only a genetically inherited TREM2 deficiency, but also environmental stimuli that do not occur in mice in the steady state.”
InfluentialPhysiology and diseases of tissue-resident macrophages
Lazarov, T., Juarez-Carreño, S., Cox, N., & Geissmann, F. (2023) · Nature · doi:10.1038/s41586-023-06002-x · Cited by 525
Suárez‐Calvet, M., Kleinberger, G., Araque Caballero, M. Á., Brendel, M., Rominger, A., Alcolea, D., Fortea, J., Lleó, A., Blesa, R., Gispert, J. D., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506123 · Cited by 522
“Heterozygous missense mutations in TREM2 also increase the risk for other neurodegenerative diseases (Borroni et al, 2013; Rayaprolu et al, 2013; Cuyvers et al, 2014), and homozygous loss-of-function mutations in TREM2 cause Nasu– Hakola disease (NHD) (Paloneva et al, 2002) and frontotemporal dementia (FTD)-like syndr…”
BackgroundInfluentialNew insights into the role of TREM2 in Alzheimer’s disease
Gratuze, M., Leyns, C. E. G., & Holtzman, D. M. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0298-9 · Cited by 489
A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia
Hsieh, C. L., Koike, M., Spusta, S. C., Niemi, E. C., Yenari, M., Nakamura, M. C., & Seaman, W. E. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06042.x · Cited by 475
“Loss-of-function mutations in either TREM2 or DAP12 cause Nasu-Hakola disease, a rare and fatal neurodegenerative disease also known as polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (Paloneva et al. 2000, 2002).”
BackgroundMapping microglia states in the human brain through the integration of high-dimensional techniques
Sankowski, R., Böttcher, C., Masuda, T., Geirsdottir, L., Sagar, Sindram, E., Seredenina, T., Muhs, A., Scheiwe, C., Shah, M. J., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0532-y · Cited by 449
Yin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
TREM2, microglia, and neurodegenerative diseases
Yeh, F. L., Hansen, D. V., & Sheng, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.008 · Cited by 440
“Unfortunately, patients with NHD usually perish in their 4th to 5th decades of life [67,68].”
BackgroundHamerman, J. A., Jarjoura, J. R., Humphrey, M. B., Nakamura, M. C., Seaman, W. E., & Lanier, L. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2051 · Cited by 440
“In humans, mutation of either DAP12 or TREM-2 results in Nasu-Hakola syndrome, a rare disease characterized by bone cysts and presenile dementia (10, 18).”
BackgroundTREM and TREM-like receptors in inflammation and disease
Ford, J. W., & McVicar, D. W. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.01.009 · Cited by 434
TREM2 in Neurodegenerative Diseases
Jay, T. R., von Saucken, V. E., & Landreth, G. E. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0197-5 · Cited by 427
“TREM2 was found to be highly expressed in white matter [101, 165], hippocampus [101, 156, 165] and spinal cord [18, 156], among other regions.”
BackgroundInfluentialRoles of microglia in brain development, tissue maintenance and repair
Michell-Robinson, M. A., Touil, H., Healy, L. M., Owen, D. R., Durafourt, B. A., Bar-Or, A., Antel, J. P., & Moore, C. S. (2015) · Brain · doi:10.1093/brain/awv066 · Cited by 425
TREM2 variants: new keys to decipher Alzheimer disease pathogenesis
Colonna, M., & Wang, Y. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.7 · Cited by 418
Ca 2+ ‐NFATc1 signaling is an essential axis of osteoclast differentiation
Negishi‐Koga, T., & Takayanagi, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00821.x · Cited by 415
Takahashi, K., Prinz, M., Stagi, M., Chechneva, O., & Neumann, H. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040124 · Cited by 414
“[23–25].”
Mechanistic insight into osteoclast differentiation in osteoimmunology
Takayanagi, H. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0612-6 · Cited by 413
Rayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W. W., Hatanpaa, K. J., Lomen-Hoerth, C., Kertesz, A., Bigio, E. H., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-19 · Cited by 404
“Recessive mutations in both TREM2 and DAP12 produce the clinical phenotype of Nasu-Hakola disease [3,11].”
Lee, C. Y. D., Daggett, A., Gu, X., Jiang, L.-L., Langfelder, P., Li, X., Wang, N., Zhao, Y., Park, C. S., Cooper, Y., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.02.002 · Cited by 396
“Complete loss of TREM2 or DAP12 leads to Nasu-Hakola disease, a recessive disorder characterized by bone cysts and early dementia (Paloneva et al., 2002), highlighting the pivotal role of TREM2 in microglia and related myeloid cells in age-dependent disease processes.”
BackgroundColonna, M. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00837-1 · Cited by 394
Cignarella, F., Filipello, F., Bollman, B., Cantoni, C., Locca, A., Mikesell, R., Manis, M., Ibrahim, A., Deng, L., Benitez, B. A., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02193-z · Cited by 418
Ontogeny and homeostasis of CNS myeloid cells
Prinz, M., Erny, D., & Hagemeyer, N. (2017) · Nature Immunology · doi:10.1038/ni.3703 · Cited by 392
Do glia drive synaptic and cognitive impairment in disease?
Chung, W.-S., Welsh, C. A., Barres, B. A., & Stevens, B. (2015) · Nature Neuroscience · doi:10.1038/nn.4142 · Cited by 385
Mackenzie, I. R. A., & Neumann, M. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13588 · Cited by 381
“These include hereditary diffuse leukoencephalopathy with spheroids, pigmented orthochromatic leukodystrophy, and Nasu-Hakola disease, which are each associated with mutations in genes related to macrophage/microglial activity (CSF1R, TREM2, and DAP12) (Paloneva et al. 2000, 2002; Rademakers et al. 2012a) and which sh…”
BackgroundGuerreiro, R. J., Lohmann, E., Brás, J. M., Gibbs, J. R., Rohrer, J. D., Gurunlian, N., Dursun, B., Bilgic, B., Hanagasi, H., Gurvit, H., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.579 · Cited by 374
“TREM2 is a single-pass type I membrane protein that forms a receptorsignaling complex with the TYRO protein tyrosine kinasebinding protein (TYROBP) and triggers activation of the immune responses in macrophages and dendritic cells.(20) TREM2 is expressed on immature dendritic cells, osteoclasts, and microglia.”
NLRP3 inflammasome-driven pathways in depression: clinical and preclinical findings
Kaufmann, F. N., Costa, A. P., Ghisleni, G., Diaz, A. P., Rodrigues, A. L. S., Peluffo, H., & Kaster, M. P. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.03.002 · Cited by 370
Microglia: Architects of the Developing Nervous System
Frost, J. L., & Schafer, D. P. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.02.006 · Cited by 363
“In addition, loss of function mutations in the microglial surface receptors DAP12 and TREM2 cause polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL; Nasu-Hakola disease) [96].”
BackgroundSoluble TREM2 induces inflammatory responses and enhances microglial survival
Zhong, L., Chen, X.-F., Wang, T., Wang, Z., Liao, C., Wang, Z., Huang, R., Wang, D., Li, X., Wu, L., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160844 · Cited by 362
“…disorders, including Nasu-Hakola disease (also known as polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy; Paloneva et al., 2002; Klünemann et al., 2005; Numasawa et al., 2011), frontotemporal dementia (Guerreiro et al., 2013b; Borroni et al., 2014; Le Ber…”
Emerging Roles for CSF-1 Receptor and its Ligands in the Nervous System
Chitu, V., Gokhan, Ş., Nandi, S., Mehler, M. F., & Stanley, E. R. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.03.005 · Cited by 362
Schmid, C. D., Sautkulis, L. N., Danielson, P. E., Cooper, J., Hasel, K. W., Hilbush, B. S., Sutcliffe, J. G., & Carson, M. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01243.x · Cited by 351
“Individuals lacking either a functional TREM-2 or DAP12 gene develop cognitive deficits in their late 20s and early 30s, coupled with the appearance of cortical plaques and death in their 40s (Paloneva et al. 2000; Paloneva et al. 2001; Paloneva et al. 2002).”
BackgroundSankowski, R., Mader, S., & Valdés-Ferrer, S. I. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00028 · Cited by 351
“…Expressing cells Consequence of mutation TREM2 AD (Guerreiro et al., 2013; Jonsson et al., 2013), PD (Rayaprolu et al., 2013), FTD (Rayaprolu et al., 2013), Nasu–Hakola disease (Paloneva et al., 2002) Anti-inflammatory, pro-phagocytic Myeloid cells Loss-of-function (Kleinberger et al., 2014)”
BackgroundInitiative, F. T. A. D. N., Suárez-Calvet, M., Morenas-Rodríguez, E., Kleinberger, G., Schlepckow, K., Araque Caballero, M. Á., Franzmeier, N., Capell, A., Fellerer, K., Nuscher, B., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0301-5 · Cited by 347
Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice
Kaifu, T., Nakahara, J., Inui, M., Mishima, K., Momiyama, T., Kaji, M., Sugahara, A., Koito, H., Ujike-Asai, A., Nakamura, A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16923 · Cited by 343
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status
Piccio, L., Deming, Y., Del-Águila, J. L., Ghezzi, L., Holtzman, D. M., Fagan, A. M., Fenoglio, C., Galimberti, D., Borroni, B., & Cruchaga, C. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1533-5 · Cited by 337
“Overall, these findings indicate that AD and NHD-associated variants can predispose to CNS pathology by different functional mechanisms.”
BackgroundInfluentialImmune Signaling in Neurodegeneration
Hammond, T. R., Marsh, S. E., & Stevens, B. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.016 · Cited by 336
“Shortly after its discovery, a set of homozygous TREM2 loss-of-function variants were found to be one cause of a very rare genetic disorder known as Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOSL) or Nasu-Hakola Disease (Klünemann et al., 2005; Paloneva et al., 2002).”
BackgroundMyeloid Cells in the Central Nervous System
Herz, J., Filiano, A. J., Wiltbank, A. T., Yogev, N., & Kipnis, J. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.007 · Cited by 332
“Mutations in key myeloid genes are associated with numerous neurological disorders (Naj et al., 2011; Paloneva et al., 2002; Rademakers et al., 2011).”
BackgroundElucidating the Role of TREM2 in Alzheimer’s Disease
Ulrich, J. D., Ulland, T. K., Colonna, M., & Holtzman, D. M. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.042 · Cited by 325
“Loss-of-function mutations in TREM2 or TYROBP, the gene that encodes DAP12, are associated with Nasu Hakola disease (NHD), an autosomal recessive disorder hallmarked by bone cysts, frequent bone fractures, and a presenile form of frontal-lobe dementia (Paloneva et al., 2001, 2002).”
BackgroundMicroglial Physiology and Pathophysiology: Insights from Genome-wide Transcriptional Profiling
Crotti, A., & Ransohoff, R. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.013 · Cited by 323
DAP10‐ and DAP12‐associated receptors in innate immunity
Lanier, L. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00720.x · Cited by 323
Jiang, T., Tan, L., Zhu, X.-C., Zhang, Q.-Q., Cao, L., Tan, M.-S., Gu, L.-Z., Wang, H.-F., Ding, Z.-Z., Zhang, Y.-D., et al. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.164 · Cited by 320
Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis
Takegahara, N., Takamatsu, H., Toyofuku, T., Tsujimura, T., Okuno, T., Yukawa, K., Mizui, M., Yamamoto, M., Prasad, D. V. R., Suzuki, K., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1416 · Cited by 320
“Also in the skeletal tissues, the defects in the DAP12 gene, as well as the Trem-2 gene, are known to result in impaired differentiation of osteoclast”
BackgroundDAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features
Paloneva, J., Mandelin, J., Kiialainen, A., Böhling, T., Prudlo, J., Hakola, P., Haltia, M., Konttinen, Y. T., & Peltonen, L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030027 · Cited by 318
“We have recently identified mutations in all PLOSL patients either in DAP12 or TREM2 (4, 5).”
BackgroundMethodInfluentialSelf-citationTREM2 Promotes Microglial Survival by Activating Wnt/β-Catenin Pathway
Zheng, H., Jia, L., Liu, C.-C., Rong, Z., Zhong, L., Yang, L., Chen, X.-F., Fryer, J. D., Wang, X., Zhang, Y.-W., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2459-16.2017 · Cited by 317
“Individuals with genetic mutations inactivating TREM2 or DAP12 develop Nasu– Hakola disease with cystic-like lesions of the bone and brain demyelination, respectively, leading to fractures and presenile dementia (Paloneva et al., 2002; Klünemann et al., 2005), implying a critical role of TREM2 in maintaining the homeo…”
BackgroundOtero, K., Turnbull, I. R., Poliani, P. L., Vermi, W., Cerutti, E., Aoshi, T., Tassi, I., Takai, T., Stanley, S. L., Miller, M., et al. (2009) · Nature Immunology · doi:10.1038/ni.1744 · Cited by 315
Microglial clearance function in health and disease
Napoli, I., & Neumann, H. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.06.046 · Cited by 313
Genes associated with Alzheimer's disease: an overview and current status
Giri, M., Lü, Y., & Zhang, M. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s105769 · Cited by 311
The identity and function of microglia in neurodegeneration
Song, W. M., & Colonna, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0212-1 · Cited by 308
Phagocytosis in the Brain: Homeostasis and Disease
Galloway, D. A., Phillips, A. E. M., Owen, D. R. J., & Moore, C. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00790 · Cited by 307
“Nasu-Hakola disease (51) Primary microglia from TREM2−/− mice Decreased phagocytosis of Aβ relative to WT”
MethodPiccio, L., Buonsanti, C., Cella, M., Tassi, I., Schmidt, R. E., Fenoglio, C., Rinker, J., Naismith, R. T., Panina-Bordignon, P., Passini, N., et al. (2008) · Brain · doi:10.1093/brain/awn217 · Cited by 307
“1C), which was characterized by a TREM-2 mutation that leads to a truncated protein (Paloneva et al., 2002; Salmaggi et al., 2003).”
BackgroundNeuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases
Rauf, A., Badoni, H., Abu-Izneid, T., Olatunde, A., Rahman, M. M., Painuli, S., Semwal, P., Wilairatana, P., & Mubarak, M. S. (2022) · Molecules · doi:10.3390/molecules27103194 · Cited by 306
“Initially, the interest in the role of neurodegeneration and TREM2 started in the 2000s when links were discovered between TREM2 and Nasu-Hakola disease and polycystic lipomembranous osteodysplasia with sclerosing [76,77].”
BackgroundRetractedThe Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E
Bailey, C. C., DeVaux, L. B., & Farzan, M. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.677286 · Cited by 303
“Homozygous lossof-function mutations in either TREM2 or TYROBP cause the Nasu-Hakola phenotype underscoring the importance to TREM2 signaling to homeostasis (7, 8).”
BackgroundIncreased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0071-x · Cited by 303
“Homozygous mutations in the triggering receptor expressed on myeloid cells 2 (TREM2) are known to cause polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, also known as Nasu-Hakola disease (NHD) [1, 2].”
BackgroundAltered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2
Ulrich, J. D., Finn, M. B., Wang, Y., Shen, A., Mahan, T. E., Jiang, H., Stewart, F. R., Piccio, L., Colonna, M., & Holtzman, D. M. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-20 · Cited by 302
“Individuals that are homozygous for loss of function mutations in either TREM2 or TYROBP (DAP12) suffer from polycystic lipomembranous osteodysplasia and sclerosing leukoencephalopathy (PLOSL) which is characterized by early onset dementia and cystic bone lesions [6].”
BackgroundMicroglial TREM2/DAP12 signaling: a double-edged sword in neural diseases
Konishi, H., & Kiyama, H. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00206 · Cited by 300
TREM2 regulates microglial cell activation in response to demyelination in vivo
Cantoni, C., Bollman, B., Licastro, D., Xie, M., Mikesell, R., Schmidt, R., Yuede, C. M., Galimberti, D., Olivecrona, G., Klein, R. S., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1388-1 · Cited by 296
“More than 10 years ago it was described that human genetic deficiency of the microglial receptor TREM2 leads to a neurodegenerative disease, PLOSL, characterized by severe brain atrophy with major white matter involvement and diffuse neuronal and axonal loss [61].”
Wunderlich, P., Glebov, K., Kemmerling, N., Tien, N. T., Neumann, H., & Walter, J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.517540 · Cited by 296
“The physiological relevance of TREM2 and DAP12 is demonstrated by loss-of-function mutations of either gene that cause polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL or Nasu-Hakola disease) associated with presenile dementia in the fourth decade of life in homozygous carriers (8, 9…”
BackgroundMicroglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293
“Mutations in TREM2 are linked to Nasu-Hakola disease (Paloneva et al., 2002), and heterozygous variants have been associated with an increased risk of developing LOAD (Guerreiro et al.”
BackgroundPattern Recognition by TREM-2: Binding of Anionic Ligands
Daws, M. R., Sullam, P. M., Niemi, E. C., Chen, T. T., Tchao, N. K., & Seaman, W. E. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.594 · Cited by 291
“TREM-2 expression has been demonstrated on microglia (18) and the capacity of TREM-2 to bind to glial cells (astrocytomas) may relate to the clinical syndrome in humans with mutations in TREM-2, which includes brain degeneration as well as dysplasia of bones (8).”
BackgroundMicroglia in the Cerebral Cortex in Autism
Tetreault, N. A., Hakeem, A. Y., Jiang, S., Williams, B. A., Allman, E., Wold, B. J., & Allman, J. M. (2012) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-012-1513-0 · Cited by 288
Blockade of TREM‐2 exacerbates experimental autoimmune encephalomyelitis
Piccio, L., Buonsanti, C., Mariani, M., Cella, M., Gilfillan, S., Cross, A. H., Colonna, M., & Panina‐Bordignon, P. (2007) · European Journal of Immunology · doi:10.1002/eji.200636837 · Cited by 284
TREM2-Ligand Interactions in Health and Disease
Kober, D. L., & Brett, T. J. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.04.004 · Cited by 284
“The TREM2 variants include splice site [7, 9] early stop sites [7, 10–12], and coding ectodomain mutations [7, 8, 13–15].”
BackgroundColonna, M., & Facchetti, F. (2003) · The Journal of Infectious Diseases · doi:10.1086/374754 · Cited by 281
“In addition, recent evidence demonstrates that a rare genetically inherited deficit of TREM-2 leads to a severe disease characterized by presenile dementia and bone cysts [35].”
BackgroundNeuroinflammation in frontotemporal dementia
Bright, F., Werry, E. L., Dobson-Stone, C., Piguet, O., Ittner, L. M., Halliday, G. M., Hodges, J. R., Kiernan, M. C., Loy, C. T., Kassiou, M., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0231-z · Cited by 280
Arcuri, C., Mecca, C., Bianchi, R., Giambanco, I., & Donato, R. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00191 · Cited by 279
“In unstimulated microglia, TREM2 is highly expressed and its expression strictly overlaps with DAP12 gene expression (Paloneva et al., 2002) and is downregulated by LPS and IFN-γ (Schmid et al.”
BackgroundInfluentialSuárez-Calvet, M., Araque Caballero, M. Á., Kleinberger, G., Bateman, R. J., Fagan, A. M., Morris, J. C., Levin, J., Danek, A., Ewers, M., Haass, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1767 · Cited by 272
Metadata
- Authors
- Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., Tranebjærg, L., Konttinen, Y., & Peltonen, L.
- Affiliations
- University of Helsinki (FI)
- University of California, Los Angeles (US)
- Umeå University (SE)
- University of Washington (US)
- Hospital Universitario La Paz (ES)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- Bispebjerg Hospital (DK)
- Helsinki University Hospital (FI)
- Corresponding author
- Peltonen, Leena
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 71
- Issue
- 3
- Pages
- 656-662
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC379202
- OpenAlex
- W2014200126
- Cited by
- 683
- References
- 29
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 27 · 2023: 35 · 2022: 37 · 2021: 48 · 2020: 47 · 2019: 34 · 2018: 54 · 2017: 53 · 2016: 38 · 2015: 42 · 2014: 29 · 2013: 28 · 2012: 11
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 3974 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Lastentautien Tutkimussäätiö
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Nasu-Hakola disease, TREM2, TYROBP, DAP12, receptor signaling complex, genetic heterogeneity, progressive dementia, bone cysts, recessive inheritance
- MeSH terms
- Triggering Receptor Expressed on Myeloid Cells-1, Actins, Female, Haplotypes, Humans, Male, Membrane Glycoproteins, Membrane Proteins, Molecular Sequence Data, Mutation, Pedigree, Phenotype, Receptors, Immunologic, RNA, Messenger, Signal Transduction, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, Protein Subunits, Macromolecular Substances, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.